Celtarys Research, founded in 2021 and headquartered in Spain, is a biotechnology company that innovatively combines chemistry to enhance biological understanding, as encapsulated in their slogan: "Innovative Chemistry to Illuminate Biology." The company specializes in developing and commercializing chemical tools to promote fluorescence-based methodologies in drug discovery.
Their proprietary chemical conjugation technology enables the swift, competitive production of customized fluorescent ligands in less than three months, optimizing pharmacological and photophysical attributes for any druggable target. Initially focusing on GPCR ligands, Celtarys Research offers a diverse catalog of 20 fluorescent ligands, validated across multiple HTS assays, avoiding radioactivity usage.
In September 2021, the company secured a €650K Seed Round investment, led by VIGO ACTIVO SOCIEDAD DE CAPITAL RIESGO DE REGIMEN SIMPLIFICADO SA and Xesgalicia, reinforcing its scalable and cost-efficient production capabilities. With strong industry potential, Celtarys Research offers promising returns for investors.